Company Overview of PharmAbcine, Inc.
PharmAbcine, Inc., a biotechnology company, develops human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. PharmAbcine, Inc. is headquartered in Daejeon, South Korea.
461-8, Daejeon BioventureTown
82 4 2863 2017
82 4 2863 2080
Key Executives for PharmAbcine, Inc.
PharmAbcine, Inc. Key Developments
Similar Private Companies By Industry
|Advanced Protein Technologies Corporation||Asia|
|Aetna Genetech Inc.||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PharmAbcine, Inc., please visit www.pharmabcine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.